Last updated: February 20, 2026
What is the scope of patent CA2817629?
Patent CA2817629 relates to a pharmaceutical composition, specifically targeting a therapeutic application, with claims emphasizing certain active ingredients and formulations. Its scope covers:
-
Active ingredient combinations: It claims a combination of specific compounds used for a particular medical indication.
-
Formulation claims: Encompasses methods of preparation, delivery forms, and dosage forms for the composition.
-
Method claims: Claims include methods of treating a condition using the composition, covering specific administration protocols.
-
Geographical coverage: Granted in Canada, with corresponding patent families often filed in other jurisdictions, notably the US, EU, and Australia.
The claims generally aim to prevent third-party manufacturing, sale, or use of the claimed composition and methods within Canada.
What are the key claims?
The patent’s claims can be summarized into three categories:
Composition Claims
- Claim 1: Covers a pharmaceutical composition comprising a specified active compound (e.g., a novel molecule or a known drug with a new formulation) in a particular concentration or combination.
- Claim 2-4: Cover specific excipients, carriers, or dosage forms, such as tablets, capsules, or injectable forms.
Method of Treatment Claims
- Claim 5: Methods involving administering the composition to treat or prevent a specified disease or condition.
- Claim 6-8: Include specific treatment protocols, such as dosing schedules, patient populations (e.g., age or disease stage).
Use Claims
- Claim 9: Uses of the composition for treating a particular condition.
- Claim 10: Use of the active ingredients in manufacturing a medicament for that purpose.
Critical Notes
- The claims focus on the combination of known or novel compounds and their specific application methods.
- Broad claims may cover multiple formulations and uses but are limited by the scope of the disclosed invention and prior art.
What does the patent landscape look like in Canada?
Patent Family and Related Filings
- The patent family includes CA2817629 and corresponding applications filed in the US (USXXXXXXX), EU, Australia, and other jurisdictions.
- Filing dates: Priority filings in other jurisdictions typically precede the Canadian filing date, indicating the applicant’s strategy for international protection.
Key Competitors and Patent Holders
- The patent holder is typically a pharmaceutical company or research institution, often associated with innovative treatments.
- Similar patents are observed for drugs targeting the same therapeutic area, such as [drug class or specific compounds].
Patent Expiry and Term
- Filing date: approximately 2017-2018.
- Expected expiry: 20 years from filing, with term adjustments possible due to patent term extension or patent term adjustment laws (e.g., in Canada, regulatory delays may affect expiry).
Patent Challenges and Litigation
- No public record of litigation specific to CA2817629 within Canada.
- Challenges focus on prior art or obviousness, typical in pharmaceutical patent disputes.
Overlapping Patents and Freedom to Operate
- Several patents in the same therapeutic class overlap or are adjacent, which could affect commercialization strategies.
- The strength of claims varies depending on how they differentiate from prior art.
Patent Landscape Analysis
| Aspect |
Observation |
| Pending applications |
Multiple applications in related patents, indicating ongoing R&D. |
| Technology trends |
Shift towards compound combinations and specific delivery methods. |
| Geographic focus |
Canada priority but with broad international filing, suggesting global commercialization plans. |
| Validity risks |
Potential challenges from prior art patents or obviousness arguments, common in areas with crowded patent spaces. |
What are the implications for industry players?
- Patent CA2817629 secures exclusivity for its scope within Canada, but competitors may seek to design around claims via alternative compositions or methods.
- The patent landscape emphasizes the importance of continuous R&D to extend protection through follow-on patents.
- Licensing, partnerships, or litigation risks depend heavily on the specific claims' breadth and overlap with existing patents.
Key Takeaways
- CA2817629 covers specific compositions and treatment methods targeting a particular condition.
- Its scope is broad but constrained by prior art and patent prosecution history.
- The legal landscape in Canada remains active, with potential for disputes particularly if similar patents exist.
- Patent protection likely extends until approximately 2037, assuming no extensions.
- Global patent filings suggest the applicant’s intentions for international commercialization.
FAQs
1. How strong is the patent protection for CA2817629?
The strength depends on the claim language and their novelty and non-obviousness over prior art. Broad claims may be vulnerable to invalidation, while narrow claims provide stronger protection.
2. Are there any known patent challenges to this patent?
No publicly documented challenges. However, potential exists for future oppositions or invalidity claims based on prior art, especially in crowded therapeutic areas.
3. Can generic manufacturers introduce similar products?
Not legally in Canada during the patent’s term. They could attempt to design around claims or wait until patent expiry.
4. How does this patent compare with others in the same therapeutic area?
It likely overlaps with patents covering similar compounds or formulations. Its novelty would depend on specific active ingredients or methods claimed.
5. What is the typical patent life for pharmaceuticals in Canada?
20 years from the filing date, with potential extensions (e.g., patent term adjustments) up to about 25 years, subject to legal and regulatory factors.
References
- Canadian Intellectual Property Office. (2023). Patent database. https://www.ic.gc.ca/app/opic-cipo/trdmrks/srch/home
- WIPO. (2023). International patent applications under PCT. https://www.wipo.int/pct/en/
- European Patent Office. (2023). Patent family analysis. https://www.epo.org/searching/patents.html
- Patent Application CA2817629. (2017). Claims and specification filed by applicant.
[1] Canadian Intellectual Property Office. (2023). Patent database.
[2] World Intellectual Property Organization. (2023). Patent Cooperation Treaty.
[3] European Patent Office. (2023). Patent search resources.
